Travis S. Laferriere-Holloway

Dr. Travis S. Laferriere-Holloway

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2023 in Nature
Verified
Journal Article
Open access
PDF file
MHMingqi Han
Mingqi Han
EBEric A. Bushong
Eric A. Bushong
MSMayuko Segawa
Mayuko Segawa
ATAlexandre Tiard
Alexandre Tiard
AWAlex Wong
Alex Wong
DSDavid B. Shackelford
David B. Shackelford
Mitochondria are critical to the governance of metabolism and bioenergetics in cancer cells1. The mitochondria form highly organized networks, in which their outer and inner membrane structures define their bioenergetic capacity2,3. However, in vivo studies delineating the relationship between the structural organization of mitochondrial networks and their bioenergetic activity have been limited. Here we present an in vivo structural and functional analysis of mitochondrial networks and bioenergetic phenotypes in non-small cell lung cancer (NSCLC) using an integrated platform consisting of positron emission tomography imaging, respirometry and three-dimensional scanning block-face electron microscopy. The diverse bioenergetic phenotypes and metabolic dependencies we identified in NSCLC tumours align with distinct structural organization of mitochondrial networks present. Further, we discovered that mitochondrial networks are organized into distinct compartments within tumour cells. In tumours with high rates of oxidative phosphorylation (OXPHOSHI) and fatty acid oxidation, we identified peri-droplet mitochondrial networks wherein mitochondria contact and surround lipid droplets. By contrast, we discovered that in tumours with low rates of OXPHOS (OXPHOSLO), high glucose flux regulated perinuclear localization of mitochondria, structural remodelling of cristae and mitochondrial respiratory capacity. Our findings suggest that in NSCLC, mitochondrial networks are compartmentalized into distinct subpopulations that govern the bioenergetic capacity of tumours.

13 December 2019 in Reaction Chemistry & Engineering
Verified
Journal Article
Closed access
PDF file
JWJia Wang
Jia Wang
TLTravis S. Laferriere-Holloway
Travis S. Laferriere-Holloway
KLKsenia Lisova
Ksenia Lisova
RDR. Michael Van Dam
R. Michael Van Dam
The first microscale radiosynthesis of the radiopharmaceutical [18F]FDOPA is developed using a green and efficient approach.

21 November 2022 in Journal of Chromatography A
Verified
Journal Article
Closed access
TLTravis S. Laferriere-Holloway
Travis S. Laferriere-Holloway
ARAlejandra Rios
Alejandra Rios
YLYingqing Lu
Yingqing Lu
COChelsea C. Okoro
Chelsea C. Okoro
RDR. Michael Van Dam
R. Michael Van Dam

24 November 2022 in Molecules
Verified
Journal Article
Open access
PDF file
TLTravis S. Laferriere-Holloway
Travis S. Laferriere-Holloway
ARAlejandra Rios
Alejandra Rios
GCGiuseppe Carlucci
Giuseppe Carlucci
RDR. Michael Van Dam
R. Michael Van Dam
Before formulating radiopharmaceuticals for injection, it is necessary to remove various impurities via purification. Conventional synthesis methods involve relatively large quantities of reagents, requiring high-resolution and high-capacity chromatographic methods (e.g., semi-preparative radio-HPLC) to ensure adequate purity of the radiopharmaceutical. Due to the use of organic solvents during purification, additional processing is needed to reformulate the radiopharmaceutical into an injectable buffer. Recent developments in microscale radiosynthesis have made it possible to synthesize radiopharmaceuticals with vastly reduced reagent masses, minimizing impurities. This enables purification with lower-capacity methods, such as analytical HPLC, with a reduction of purification time and volume (that shortens downstream re-formulation). Still, the need for a bulky and expensive HPLC system undermines many of the advantages of microfluidics. This study demonstrates the feasibility of using radio-TLC for the purification of radiopharmaceuticals. This technique combines high-performance (high-resolution, high-speed separation) with the advantages of a compact and low-cost setup. A further advantage is that no downstream re-formulation step is needed. Production and purification of clinical scale batches of [18F]PBR-06 and [18F]Fallypride are demonstrated with high yield, purity, and specific activity. Automating this radio-TLC method could provide an attractive solution for the purification step in microscale radiochemistry systems.

2 December 2022 in Analytical Methods
Verified
Journal Article
Closed access
PDF file
TLTravis S. Laferriere-Holloway
Travis S. Laferriere-Holloway
ARAlejandra Rios
Alejandra Rios
RDR. Michael Van Dam
R. Michael Van Dam
Aqueous mobile phases lead to complex migration of analytes in radio-TLC performed on silica plates.